Journal article
A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: The handling erythropoietin resistance with oxpentifylline (HERO) trial
DW Johnson, EM Pascoe, SV Badve, K Dalziel, A Cass, P Clarke, P Ferrari, SP McDonald, AT Morrish, E Pedagogos, V Perkovic, D Reidlinger, A Scaria, R Walker, LA Vergara, CM Hawley, E D'Almeida, R Fassett, C Kirkpatrick, R Phoon Show all
American Journal of Kidney Diseases | Published : 2015
Abstract
Background: Erythropoiesis-stimulating agent (ESA)-hyporesponsive anemia is common in chronic kidney disease (CKD). Pentoxifylline shows promise as a treatment for ESA-hyporesponsive anemia, but has not been rigorously evaluated. Study Design: Multicenter, double-blind, randomized, controlled trial. Setting & Participants: 53 adult patients with CKD stage 4 or 5 (including dialysis) and ESA-hyporesponsive anemia (hemoglobin ≤ 120 g/L and ESA resistance index [calculated as weight-adjusted weekly ESA dose in IU/kg/wk divided by hemoglobin concentration in g/L] ≥ 1.0 IU/kg/wk/g/L for erythropoietin-treated patients and ≥0.005 μg/kg/wk/g/L for darbepoetin-treated patients). Interventions: Pento..
View full abstractGrants
Funding Acknowledgements
Dr Johnson has previously received consultancy fees from Sanofi-Aventis and consultancy fees, speakers' honoraria, research grants, and travel sponsorships from Amgen, Roche, and Janssen-Cilag. He was the recipient of a RoFAR grant, which partly funded the HERO trial, and a Queensland Government Health Research Fellowship. Dr Hawley has previously received consultancy fees, speakers' honoraria, research grants, and/or travel sponsorships from Amgen, Roche, and Janssen-Cilag. Dr Cass has previously received consultancy fees, speakers' honoraria, and/or research grants from Amgen, Roche, Baxter, Fresenius, and Merck. Dr Walker has previously received consultancy fees, speakers' honoraria, research grants, and travel sponsorships from Amgen, Roche, and Janssen-Cilag and has served on Advisory Boards for Amgen, Roche, and Janssen-Cilag. The other authors declare that they have no other relevant financial interests.